A Single-centre, Double-blind (Sponsor Open), Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 as a Dry Powder in Healthy Participants Who Smoke Cigarettes
Phase of Trial: Phase I
Latest Information Update: 02 Sep 2017
At a glance
- Drugs GSK 2292767 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors GlaxoSmithKline
- 28 Aug 2017 Status changed from recruiting to completed.
- 06 Jul 2017 Planned End Date changed from 4 Aug 2017 to 23 Aug 2017.
- 06 Jul 2017 Planned primary completion date changed from 13 Jul 2017 to 1 Aug 2017.